WO2000015207A2 - Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) - Google Patents
Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) Download PDFInfo
- Publication number
- WO2000015207A2 WO2000015207A2 PCT/IB1999/001547 IB9901547W WO0015207A2 WO 2000015207 A2 WO2000015207 A2 WO 2000015207A2 IB 9901547 W IB9901547 W IB 9901547W WO 0015207 A2 WO0015207 A2 WO 0015207A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- elastase
- antibacterial agent
- syn
- group
- elastase inhibitor
- Prior art date
Links
- 0 C*CNC(c1ccccc1NS(c(cc1)ccc1OC(C)=O)(=O)=O)=O Chemical compound C*CNC(c1ccccc1NS(c(cc1)ccc1OC(C)=O)(=O)=O)=O 0.000 description 1
- UHOQZAIRJTXHNM-UHFFFAOYSA-N CC(C)(CS(C1C=CC(OC(C(C)(C)c2ccc(C(C)(C)C(OC(CC3)=CC=C3S(CC(C)(C)C(O)=O)(=O)=O)=O)cc2)=O)=CC1)(=O)=O)C(O)=O Chemical compound CC(C)(CS(C1C=CC(OC(C(C)(C)c2ccc(C(C)(C)C(OC(CC3)=CC=C3S(CC(C)(C)C(O)=O)(=O)=O)=O)cc2)=O)=CC1)(=O)=O)C(O)=O UHOQZAIRJTXHNM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present invention relates to a method of using antibacterial agent(s), in combination with human neutrophil elastase inhibitor(s) for the treatment of inflammation, particularly inflammation associated with pulmonary disease and dental disease.
- Pulmonary inflammation has been associated with aberrant levels of or aberrant activity of human neutrophil elastase (HNE), a member of the family of serine proteases.
- HNE human neutrophil elastase
- HNE is known to degrade a variety of connective tissue proteins. HNE has been implicated in the pathogenesis of several chronic inflammatory diseases of the lung.
- HNE proteolytic activity
- the primary guardian against connective tissue destruction is alpha-1 protease inhibitor ( ⁇ ,-PI).
- ⁇ ,-PI alpha-1 protease inhibitor
- pathological conditions may arise, for example, when ⁇ ,-PI levels are genetically low, or when ⁇ ,-PI has been oxidized or degraded, or when access to HNE is restricted.
- Disease states resulting from uncontrolled elastase activity include, for example, cystic fibrosis, rheumatoid arthritis, bronchitis, bronchiectasis, emphysema, adult respiratory distress syndrome, periodontitis and other related diseases.
- a number of synthetic HNE inhibitors have shown some effectiveness in treating inflammation resulting from uncontrolled elastase activity, particularly in the lung.
- a combined therapeutic comprising a suitable antibacterial agent and an elastase inhibitor is used to treat inflammation associated with elastase mediated inflammatory diseases like cystic fibrosis, bronchiectasis, chronic bronchitis, periodontitis and gingivitis.
- elastase mediated inflammatory diseases like cystic fibrosis, bronchiectasis, chronic bronchitis, periodontitis and gingivitis.
- a suitable antibacterial agent will depend on the nature and level of the disease state.
- cystic fibrosis and bronchiectasis an antibacterial agent effective against Pseudomonas aeruginosa and/or Burkholderia cepacia will be highly desirable.
- an antibacterial agent effective particularly against Hemophilus influenzae is desirable.
- an antibacterial agent effective against major oral pathogens involved in gingivitis and/or periodontitis will be a suitable choice.
- pulmonary diseases include, for example, cystic fibrosis (CF), chronic bronchitis, bronchiectasis, and related elastase-mediated disorders.
- Suitable diseases of the oral cavity include for example, periodontitis and gingivitis.
- at least one antibacterial agent is administered in combination with at least one elastase inhibitor to treat such disorders.
- a combination of at least one antipseudomonal antibacterial agent and at least one elastase inhibitor is an effective therapy for such disease. Indeed, it is shown that a combination of anti-pseudomonal agent and an elastase inhibitor is more effective as a therapeutic agent in improving lung condition than is an anti-pseudomonal agent or elastase inhibitor alone.
- a preferred embodiment of the present invention describes the treatment of elastase mediated disorders, particularly of the lung, such as CF, with a combination of anti- pseudomonal antibacterial agent and elastase inhibitor.
- the combination approach preferably useful for treatment of cystic fibrosis can be used effectively for other inflammatory diseases.
- disease states in which aberrant HNE activity is implicated are targets of the combined approach of the invention.
- chronic bronchitis, bronchiectasis, periodontitis, and related disorders are treated according to the invention.
- elastase inhibitors useful according to the invention include cephalosporin sulfone derivatives, most preferably, Syn 1390 and Syn 1396, which are described in U.S. Patents 5,439,904, incorporated by reference herein in its entirety.
- Elastase inhibitors acceptable for the combined therapy include both those of the beta-lactam skeleton, or non-beta lactam skeleton.
- elastase inhibitors useful in the context of the present invention include, but are not limited to: SLPI; ⁇ ,-AT; DMP 777; ONO 5046; ICI 200,800; ICI 200,355; L- 658, 758; L-659, 286; CE-1037; SYN 1390; SYN 1396, whose structures appear below:
- Antibacterial agents employed in the present invention include a variety of agents, most preferably, agents directed against Pseudomonas aeruginosa, Hemophilus influenzae, Burkholderia cepacia, and major oral pathogens.
- antibiotics include agents from the ⁇ -lactam class, quinolone class, aminoglycoside class, macrolide class, tetracycline class, cationic peptide class and the like.
- Preferred antibacterial agents from the ⁇ -lactam class include, for example, ceftazidime, cefpirome, cefepime, cefoperazone, imipenem, meropenem, piperacillin, mezlocillin, ticarcillin, the combination of piperacillin and tazobactam, the combination of ticarcillin and clavulanic acid, and BMS- 180680 (Bristol Myers and Squibb) including their pharmaceutically acceptable salts.
- Preferred agents from the quinolone class include, for example, norfloxacin, ciprofloxacin, ofloxacin, lomefloxacin, pefloxacin, rufloxacin, and sparfloxacin, including their pharmaceutically acceptable salts.
- Representative compounds from the aminoglycoside class include, for example, tobramycin, amikacin, gentamicin, and netlimicin, including their pharmaceutically acceptable salts.
- Representative compounds from the macrolide class include erythromycin, clarithromycin, and azithromycin, including their pharmaceutically acceptable salts.
- Representative compounds from tetracycline class include tetracycline, oxytetracycline, doxycycline, and minocycline, including their pharmaceutically acceptable salts.
- Other antibacterial agents included in this invention are: IB-367 (Intrabiotics Pharm, Inc., Mountainview, California, USA), and daptomycin (Cubist), and daptomycin (Cubist), and dap
- a preferred antibacterial agent is triclosan, and related chemical entities used in dental care products, such as, toothpaste, oral rinse, and the like.
- a kit is provided that is suitable for use in treatment of inflammation associated with elastase-mediated pulmonary disease in a patient in need of such treatment.
- a kit provides at least two separately packaged containers, a first container comprising an effective amount of at least one antibacterial agent according to the present invention, and a second container comprising at least one agent that is an elastase inhibitor in humans.
- Either of the first or second container preferably dispenses an aerosol spray.
- a container according to the invention may be a vial, blister pack, or other conventional means for holding a pharmaceutically active agent.
- DOSAGE In general, a daily dose of an effective elastase inhibitor or pharmaceutically acceptable salt thereof, of between 1.0 mg and 500 mg per kilogram of body weight, per day, may be administered to a patient, together with the antibacterial agent .
- the weight ratio of elastase inhibitor to antibiotic with which is administered will normally be in the range of from 1 :50 to 50: 1 , and preferably 1 :20 to 20: 1. Dose level, however, may vary and depend upon a variety of factors, for example, the activity of the specific compounds employed, the age, body weight, sex, and diet of the patient, and the route of administration.
- the combined therapeutical agent of the present invention will be administered preferably in aerosolized form, such as through a spray or nebulizer.
- the elastase inhibitor could be administered first followed by the antibiotic or vice versa.
- Both components of the combined therapy may be delivered by orally or by intravenously as well.
- the components of the combined therapy may be delivered in the form of oral rinse, in the form of toothpaste or by injection into the gums locally.
- the combination of elastase inhibitor and antibacterial agent may be formulated as utilizing solutions, suspensions, emulsions, powders and semisolid preparations.
- preferred solvents include water, ethanol and glycols.
- preferred dispersing agents include sorbitad trioleate, oleyl alcohol, oleic acid, lecithin, and the like.
- EXAMPLE I Efficacy of combined treatment with elastase inhibitor and antibiotic in rat chronic lung infection model.
- One hundred eight rats were utilized in these experiments (27 animals in each of four groups). All animals were inoculated intratracheally with 10 5 Pseudomonas aeruginosa strain PAO in agar beads. Seven days following inoculation, rats were exposed to aerosol preparations from an Aero-Tech II nebulizer (CIS-US, Bedford, MA). The nebulizer was operated at 45 psi, with a flow rate of 10 L/min, and contained 10 ml of the preparation to be aerosolized.
- mice received daily exposure to normal saline; one treatment group received daily exposure to sub-MIC tobramycin ("Tobi"); one treatment group received daily exposure to SYN 1390 (1 mg/ml); one treatment exposure to sub-MIC Tobi plus elastase agent, SYN 1390 (1 mg/ml). Animals were sacrificed on days 0, 3 and 7.
- Control 10 ml-2.25 mg/ml NaCl per group of 9 animals
- Syn 1390 10 ml-Syn 1390 1 mg/ml) in 2.15 mg/ml Nail per group of 9 animals.
- Tobi 10 ml Tobi (lOmg/ml) in 2.25 mg/ml Nail per group of 9 animals.
- Table 1 Total cell counts and % PMN in treatment groups.
- %PMN polymorphonuclear leukocytes
- obi stand for aerosol formulation of Tobramycin (the product was obtained from Pathogenesis Corporation of Seattle, USA). Another significant observation was in Table 4, i.e., quantitative pathology on lungs from treatment group at day 7. The value with Tobi/Syn 1390 was 12.7 and the value was significantly lower than each individual control. This data indicates that the combination effectively clears the bacteria (P. aeruginosa) from the lung and the conditions of the lungs are improved.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU55282/99A AU5528299A (en) | 1998-09-15 | 1999-09-15 | Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10038698P | 1998-09-15 | 1998-09-15 | |
US60/100,386 | 1998-09-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000015207A2 true WO2000015207A2 (en) | 2000-03-23 |
WO2000015207A3 WO2000015207A3 (en) | 2000-05-25 |
WO2000015207B1 WO2000015207B1 (en) | 2000-07-13 |
Family
ID=22279479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1999/001547 WO2000015207A2 (en) | 1998-09-15 | 1999-09-15 | Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5528299A (en) |
WO (1) | WO2000015207A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049323A1 (en) * | 2000-01-06 | 2001-07-12 | Eli Lilly And Company | Combination therapy for the treatment of inflammatory and respiratory diseases |
EP1166773A1 (en) * | 2000-06-29 | 2002-01-02 | Ono Pharmaceutical Co., Ltd. | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof |
WO2002003998A2 (en) * | 2000-07-10 | 2002-01-17 | Chiron Corporation | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
WO2002064089A2 (en) * | 2001-02-13 | 2002-08-22 | Intrabiotics Pharmaceuticals, Inc. | Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial ib-367 peptides |
WO2005046692A1 (en) * | 2003-10-28 | 2005-05-26 | Bayer Healthcare Ag | Treatment of genetic diseases with the aid of quinolones, naphthyridones |
US20120010215A1 (en) * | 2003-02-10 | 2012-01-12 | Bayer Schering Pharma Aktiengesellschaft | Treatment of bacterial diseases of the respiratory organs |
CN108570418A (en) * | 2018-04-08 | 2018-09-25 | 山东农业大学 | A kind of aspergillus fumigatus agar beads and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1564317A (en) * | 1976-06-25 | 1980-04-10 | Roche Products Ltd | Dipeptide derivatives |
US4613587A (en) * | 1983-09-23 | 1986-09-23 | Yeda Research And Development Co. Ltd. | Ophthalmic preparations |
US5439904A (en) * | 1993-12-07 | 1995-08-08 | Synphar Laboratories, Inc. | 2-spiro(2'-spirocycloalkyl)cyclopropyl cephalosporin sulfones as antiinflammatory and antigenerative agents |
-
1999
- 1999-09-15 AU AU55282/99A patent/AU5528299A/en not_active Abandoned
- 1999-09-15 WO PCT/IB1999/001547 patent/WO2000015207A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1564317A (en) * | 1976-06-25 | 1980-04-10 | Roche Products Ltd | Dipeptide derivatives |
US4613587A (en) * | 1983-09-23 | 1986-09-23 | Yeda Research And Development Co. Ltd. | Ophthalmic preparations |
US5439904A (en) * | 1993-12-07 | 1995-08-08 | Synphar Laboratories, Inc. | 2-spiro(2'-spirocycloalkyl)cyclopropyl cephalosporin sulfones as antiinflammatory and antigenerative agents |
Non-Patent Citations (1)
Title |
---|
FURUNO, TAKASHI ET AL: "The role of neutrophil elastase in human pulmonary artery endothelial cel injury" INT. ARCH. ALLERGY IMMUNOL. (1997), 112(3), 262-269 ,1997, XP000879176 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049323A1 (en) * | 2000-01-06 | 2001-07-12 | Eli Lilly And Company | Combination therapy for the treatment of inflammatory and respiratory diseases |
EP1166773A1 (en) * | 2000-06-29 | 2002-01-02 | Ono Pharmaceutical Co., Ltd. | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof |
US6552082B2 (en) | 2000-06-29 | 2003-04-22 | Ono Pharmaceutical Co., Ltd. | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof |
WO2002003998A2 (en) * | 2000-07-10 | 2002-01-17 | Chiron Corporation | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
WO2002003998A3 (en) * | 2000-07-10 | 2002-06-13 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
WO2002064089A2 (en) * | 2001-02-13 | 2002-08-22 | Intrabiotics Pharmaceuticals, Inc. | Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial ib-367 peptides |
WO2002064089A3 (en) * | 2001-02-13 | 2002-12-12 | Intrabiotics Pharmaceuticals | Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial ib-367 peptides |
US20120010215A1 (en) * | 2003-02-10 | 2012-01-12 | Bayer Schering Pharma Aktiengesellschaft | Treatment of bacterial diseases of the respiratory organs |
WO2005046692A1 (en) * | 2003-10-28 | 2005-05-26 | Bayer Healthcare Ag | Treatment of genetic diseases with the aid of quinolones, naphthyridones |
CN108570418A (en) * | 2018-04-08 | 2018-09-25 | 山东农业大学 | A kind of aspergillus fumigatus agar beads and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2000015207A3 (en) | 2000-05-25 |
WO2000015207B1 (en) | 2000-07-13 |
AU5528299A (en) | 2000-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9345663B2 (en) | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections | |
JP4646489B2 (en) | Inhalable aztreonam for the treatment and prevention of pulmonary bacterial infections | |
AU2002231244A1 (en) | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections | |
EP1641436B1 (en) | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections | |
US7271239B2 (en) | D-isomers of antimicrobial peptide | |
WO2000015207A2 (en) | Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) | |
JP7389653B2 (en) | How to reduce lung infections | |
JP2005504095A (en) | Monobactam composition and method of use thereof | |
AU2014271333B2 (en) | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections | |
AU2004257632C1 (en) | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections | |
Shemin et al. | Gram-negative peritonitis in peritoneal dialysis: Improved outcome with intraperitoneal ceftazidime | |
AU2012202089A1 (en) | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
B | Later publication of amended claims | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09786372 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |